Efficacy and safety of Dengyinnaotong Capsule in patients with Cognitive impairment caused by cerebral Small Vessel Disease: study protocol of a multicenter, randomized, open-label, controlled trial (De-CSVD trial)

Yan-Xia Li¹, Jin-Cun Li¹, Min Tian¹, Mao-Yong Zheng¹, Li-Ping Zhang¹, Jin-Lu Zhang¹, Feng Yu², Yi-Zhao Li³ and Qing-Hua Zhang⁴*

Abstract

**Background:** Cerebral small vessel disease (CSVD) is a common syndrome in the older population, with a prevalence ranging from 5% in subjects aged 50 years to almost 100% in those aged 90 years and older. It is regarded to be a major cause of vascular cognitive impairment. Existing prevention and treatment approaches have not yet shown ideal clinical outcomes. Dengyinnaotong Capsule has shown great potential for improving cognitive function. This trial (De-CSVD trial) is designed to investigate the efficacy and safety of Dengyinnaotong Capsule on cognitive function in patients with CSVD.

**Methods:** This multicenter, randomized, open-label, controlled trial is planned to recruit at least 270 patients with mild cognitive impairment related to CSVD in 25 centers in China. Recruitment started on 10 May 2021 and is foreseen to end on 31 December 2022. The final follow-up of participants will be completed by the end of March 2023. Participants will be randomized in a ratio of 1:1 to the experimental group (routine basic treatment plus Dengyinnaotong Capsule) or the control group (routine basic treatment). The primary outcome is the change in the Montreal Cognitive Assessment score from baseline to week 12. Secondary outcomes are changes in Shape Trail Test, Activities of Daily Living, Geriatric Depression Scale, and Dizziness Handicap Inventory score from baseline to week 12, new vascular events, and the changes in serum level of homocysteine, high-sensitivity C-reactive protein, and D-dimer from baseline to week 4 and 12, respectively. The exploratory outcome is the changes in the Tinetti performance-oriented mobility assessment score from baseline to week 12. Safety assessment is performed by monitoring vital signs, general biochemical examinations, 12-lead electrocardiogram examinations, and incidence of cardiovascular and cerebrovascular ischemia or bleeding events. Visits will be performed at week 0 (baseline, pre-randomization), week 4, and week 12 in the treatment period (post-randomization).

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Cerebral small vessel disease (CSVD) is a quite common syndrome in the older population, with a prevalence ranging from 5% in subjects aged 50 years to almost 100% in those aged 90 years and older [1]. It affects cerebral small vessels composed of capillaries, small arteries, arterioles, venules, and small veins [2]. In the field of neuroimaging, the CSVD is marked by enlarged perivascular spaces, small subcortical infarcts, lacunes, white matter hyperintensities, cerebral microbleeds, and brain atrophy [3]. The prevalence of lacunes, white matter hyperintensities, and microbleeds in the elderly population is around 8–28%, 50–98%, and 5%, respectively [4]. In recent years, CSVD has attracted more and more attention and is regarded to be one of the main causes of vascular cognitive impairment [5, 6]. Vascular cognitive impairment is considered a gradual process from normal cognitive status to mild cognitive impairment and then dementia [7]. With the steady growth of life expectancy worldwide, the incidence rate of age-related CSVD is also increasing, leading to a high global burden of stroke and vascular dementia [8, 9]. Up to now, a healthy lifestyle, modification of traditional risk factors (such as hypertension, hypercholesterolemia, diabetes mellitus, and smoking), cholinesterase inhibitors, memantine, and selective calcium channel blockers with mainly vascular effects are still the most important preventive and therapeutic approaches for CSVD [10, 11]. However, most of these conventional treatments were limited by the frequent contraindications and adverse effects (AEs), high drug burden, and dissatisfied clinical outcomes. Therefore, developing novel treatment strategies is quite important for patients with CSVD.

Dengyinnaotong Capsule is one of the traditional Chinese medicine recipes for promoting blood flow and dispelling wind-evil. It is modified from traditional Yi medicine and consists of four herbs (Erigeron breviscapus, Leaves Ginkgo biloba, Gaultheria cumingiana, and Radix Panax notoginseng). Several studies have proved the role of the Dengyinnaotong Capsule in improving cognitive function. A preclinical study has shown that Dengyinnaotong Capsule significantly improves the learning and memory function of an aging model mouse [12]. Chen et al. have found that Dengyinnaotong Capsule combined with Naoxintong Capsule can significantly improve the nerve function and life ability of patients with cerebral infarction in the convalescent phase when compared to Naoxintong Capsule [13]. Wu et al. compared the efficacy of Dengyinnaotong Capsule and Yinxingye Capsule on the treatment of patients with ischemic stroke in the convalescent and sequelae phase [14]. The study showed that Dengyinnaotong Capsule is better than Yinxingye Capsule in terms of effective rate and improvement symptoms in the treatment of ischemic stroke. All the above evidence suggests that Dengyinnaotong Capsule might be a promising approach for treating patients with mild cognitive impairment related to CSVD.

Therefore, a multicenter, randomized, open-label, controlled trial (De-CSVD trial) is designed to investigate the efficacy and safety of Dengyinnaotong Capsule on cognitive function in patients with CSVD. We hypothesize that Dengyinnaotong Capsule plus routine basic treatment is more effective in terms of improving cognitive impairment when compared with routine basic treatment. Herein, the methods used in the ongoing De-CSVD trial are described.

Methods/design

Study design

De-CSVD is designed as a multicenter, randomized, open-label, parallel-group, exploratory trial to determine the efficacy and safety of Dengyinnaotong Capsule on cognitive function in patients with CSVD. Recruitment started on 10 May 2021 and is foreseen to end on 31 December 2022. After a screening period within 7 days, eligible participants will be randomized to the experimental group (routine basic treatment plus Dengyinnaotong Capsule) or the control group (routine basic treatment) in a 1:1 ratio. Visits will be performed at weeks 0, 4, and 12 in the treatment period. This trial was designed according to the SPRIT 2013 Statement [15]. An overview of the study design is shown in Fig. 1.

Trial setting

Participants will be recruited from 25 centers of Shandong province in China, including Shandong Second Provincial General Hospital, Heze Municipal Hospital,
Participants eligibility

The inclusion criteria of participants are as follows: (1) participants aged 50–70 years; (2) participants with cognitive decline in memory or other cognitive domains at least for 3 months, and was diagnosed with mild cognitive impairment (cognitive decline in one or more cognitive domains and is insufficient to affect the independence of life) according to the “Chinese Diagnosis and Treatment Guidelines for Cognitive Dysfunction Related to Cerebral Small Vascular Disease (2019)” [16]; (3) participants with the Montreal Cognitive Assessment (MOCA) score < 26 (does not meet the diagnostic criteria of dementia according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition [17]) and a clinical dementia rating scale (CDR) score of 0.5 points [18]; (4) head computerized tomography or magnetic resonance imaging showed recent small subcortical infarcts, lacunes, white matter hyperintensities (WMHs), enlarged perivascular spaces, and microbleeds, and according to the “Chinese Diagnosis and Treatment Guidelines for Cognitive Dysfunction Related to Cerebral Small Vascular Disease (2019)” and “Consensus on Diagnosis and Treatment of Cerebral Small Vascular Disease in China (2015)” [19] (more than 2 lacunar infarcts outside the brain stem, Fazekas score ≥ 2 and number of cerebral micro hemorrhage ≥ 3); and (5) participants with signed informed consent for trial participation.

Exclusion criteria are as follows: (1) participants with intracranial hemorrhage or massive hemorrhage of other organs; (2) participants with a history of severe mental illness or epilepsy; (3) participants with a history of new stroke within 3 months before admission; (4) participants with a history of alcohol or drug abusers; (5) participants with Alzheimer’s disease, Lewy body dementia, frontotemporal lobe dementia, brain tumors, hydrocephalus or other central nervous diseases; (6)
participants who are unable to complete neuropsychological test and magnetic resonance imaging examination; (7) participants who had participated in other drug clinical trials as subjects in the past 30 days; and (8) researchers consider it impossible for the subject to complete the study.

Withdrawal criteria from the treatment are as follows: (1) participants or their guardian withdraw informed consent; (2) participants lost to follow-up; (3) sensitivity to Dengyinaotong Capsule or their components; (4) participants experience severe complications or deterioration during the trial period in which urgent measures were required; (5) participants become pregnant during the trial; and (6) other reasons. The reason for the participant being withdrawn from the trial will be recorded. If the participant is still willing to complete the follow-up, then the follow-up process will continue.

Sample size calculation
The sample size calculation is based on previous studies [14, 20, 21]. The routine basic treatment has been proved to improve the MOCA score of patients with CSVD by 2 points [20]. Besides, the routine basic treatment combined with Yinxingye is effective in the treatment of cognitive impairment in non-demented patients, with a MOCA score improved by 3 points [21]. Moreover, Wu et al. have found that Dengyinaotong Capsule is better than Yinxingye Capsule in terms of effective rate and improvement symptoms in the treatment of ischemic stroke [14]. Therefore, based on the above results, we assume that the routine basic treatment combined with Dengyinaotong Capsule in this trial will improve the MOCA score of patients with CSVD by 2 points compared with the routine basic treatment. Accordingly, 108 per group will be sufficient with a level of significance of 95% (α=0.05), a power of 90% (β=0.1), and an assumed standard deviation (SD) of 4.5. Considering the drop-out rate of 20%, a total of 270 samples (135 per group) are needed at least.

Randomization, allocation concealment, and blinding
All eligible participants are randomly assigned to an experimental group (routine basic treatment plus Dengyinaotong Capsule) or control group (routine basic treatment) in a ratio of 1:1. The simple randomization is generated centrally by the trial biostatistician using a computer-generated random number table. A central, web-based system will provide a unique trial identifier for each participant via email to a delegated member of site staff. Due to the open-label design, the participant, investigator, and project management teams are aware of the treatment allocation.

Intervention
Participants in the control group are treated with routine basic treatment. Participants in the experimental group are treated with routine basic treatment plus Dengyinaotong Capsule (Kunming Pharmaceutical Group Co., Ltd., Yunnan, China; 0.52 g/time, 3 times/day). The routine basic treatment is performed according to the “Chinese Diagnosis and Treatment Guidelines for Cognitive Dysfunction Related to Cerebral Small Vascular Disease (2019)” and “Consensus on Diagnosis and Treatment of Cerebral Small Vascular Disease in China (2015)” [19].

The total treatment period is 12 weeks. If there are AEs during treatment, the investigators can decide whether to terminate or postpone the medication according to the severity. In addition, for other concomitant diseases, combined drugs can be used on the premise of not affecting the judgment of the efficacy of the test drugs. During the trial period, it is forbidden to use other Chinese medicines, including Chinese patent medicine, Chinese medicine injections, and Chinese medicine decoctions, decoction pieces, and formula granules.

During the trial, to ensure the compliance of participants, it is important for them to fully understand the significance of the trial, the importance of taking the medicine on time, and the necessity for follow-up. The subjects will be required to take the medicine according to the regulations, fill in the patient diary card on time, and attend the follow-up as required. In order to assess drug compliance, participants will be checked for the remaining number of drugs at each follow-up visit.

Data collection
In this trial, data collection will be performed at weeks 0, 4, and 12 in the treatment period. The schedule of data collection is shown in Table 1. General biochemical examinations include blood routine, urine routine, stool routine, coagulation function, liver function, renal function, blood glucose, and blood lipid examination.

The 30-item clinician-administered MoCA is a brief cognitive screening tool with high sensitivity for screening patients with mild cognitive impairment [22]. It is a simple 10-min paper-and-pencil test that assesses multiple cognitive domains including memory, attention, concentration, language, visuospatial skills, abstraction, calculation, executive functions, and orientation.

The clinician-administered Shape Trail Test (STT) measures the ability to shift attention and visual attention [23]. STT part A requires test-takers to connect numbers (1–25) that are randomly distributed on a test paper (1-2-3 ...). In STT part B, a number (1–25) is surrounded by either a circle or a square, and the test-takers are asked to connect the numbers in a sequence. Once the
test-taker places the pen or pencil on the first circle, the researcher will start recording the time and stop measuring the time when the pencil touches the last number. Taking the sum of completion time as the scoring standard (the shorter the time, the better the executive function) [24].

The Barthel index is a widely used tool for evaluating physical performance in Activities of Daily Living (ADL) [25]. The Barthel index includes ten items in two major areas of self-care activities (feeding, bathing, grooming, dressing, bowel and bladder control, and toileting) and mobility (including mobility, transfer, and using stairs). The score ranges from 0 (disabled) to 100 (very independent). The self-perceived level of handicap associated with the symptom of dizziness is measured by the 25-item Dizziness Handicap Inventory (DHI) [26]. Both ADL and GHI are self-report questionnaires.

The self-reported Tinetti performance-oriented mobility assessment (POMA) examines the level of mobility and balance to determine the degree of fall risk in the elderly [27]. This examination tool consists of the mobility subscale (8 items, 12 points) and balance subscale (9 items, 16 points), totaling 28 points. A higher score reflects a better functioning of the patient in mobility and balance. Depression in geriatric populations is assessed by the self-reported Geriatric Depression Scale (GDS) [28]. It is designed as a 30-item inventory with a yes/no format. A GDS score of 10 or fewer is considered normal, 11 to 20 is considered mildly depressed, and 21 or more means moderately to severely depressed.

### Outcomes

The primary outcome is the change in MoCA score from baseline to week 12. The secondary outcomes include the following: (1) the changes in STT, ADL, GDS, and DHI score from baseline to week 12; (2) new vascular events; and (3) the changes in serum level of homocysteine (Hcy), high-sensitivity C-reactive protein (HS-CRP), and D-dimer from baseline to week 4 and 12, respectively. The exploratory outcome is the changes in the Tinetti POMA score from baseline to week 12.

### Safety assessment

Safety assessment is performed at weeks 0, 4, and 12 by monitoring vital signs, general biochemical examinations, 12-lead electrocardiogram examinations, and the incidence of cardiovascular and cerebrovascular ischemia or bleeding events. All AEs observed by investigators or reported spontaneously by participants throughout the trial will be registered. For related to the trial, the investigators will give symptomatic treatment. Investigators will also collect the detailed characteristics of AEs, including reasons, grades, actions taken regarding AEs, dates of treatment initiation and end, and treatment outcomes. AEs are graded as mild, moderate, serious, life-threatening, and death. Serious AEs (SAEs) include death, a life-threatening AE, hospitalization or prolongation of hospitalization, a persistent or significant disability, a congenital anomaly, or a significant medical event that requires intervention. Any SAEs should be reported to the local Food and Drug Administration, National Medical Products Administration, and National Health and Family Planning Commission within 24 hours.

### Plans to promote participant retention and complete follow-up

Participants will receive extensive information about the study setup and requirements during the recruitment process. The importance of completing the follow-up will be stressed. The trial will maximize both enrollment and participant retention via multiple pathways, including collecting support system contact information during informed consent, appointment reminders, and support for transportation. Participants will be allowed to withdraw from treatment at any time. Participants

---

**Table 1** Schedule of data collection

| Visits | Screening and baseline | Treatment period |
|-------|-----------------------|------------------|
|       | 0                     | 1                | 2                |
| Time points (weeks) | − 1 to 0 | 4 | 12 |
| Time windows (days)  | ±7         | ±7             | ±7             |
| Informed consent     | x          |                |                |
| Inclusion and exclusion criteria | x |              |                |
| History of diagnosis and treatment | x | | |
| Vital signs and physical examinations | x | x | x |
| General biochemical examinations | x | x | x |
| 12-lead electrocardiogram examination | x | x³ | x |
| CT or MRI examination | x | x³ | x³ |
| MoCA score | x | | |
| CDR score | x | | |
| Shape Trail Test | x³ | x³ | x³ |
| ADL score | x | | |
| DHI score | x³ | x³ | x³ |
| Tinetti POMA score | x³ | x³ | x³ |
| GDS score | x³ | x³ | x³ |
| Serum levels of Hcy, HS-CRP, and D-dimer | x³ | x³ | x³ |
| Audiological examination | x³ | x³ | x³ |
| Drug combination | x | | |

MoCA Montreal Cognitive Assessment, CDR Clinical Dementia Rating, CT Computed tomography, MRI Magnetic resonance imaging, ADL Activities Of Daily Living, DHI Dizziness Handicap Inventory, Tinetti POMA Tinetti performance-oriented mobility assessment, GDS Geriatric Depression Scale, Hcy homocysteine, HS-CRP High-sensitivity C-reactive protein

* For patients with relevant clinical manifestations or willing to be examined
who prematurely exit the study will still be encouraged to participate in regular follow-up visits, ensuring data will continue to be collected.

**Statistical analysis**

The efficacy analysis is based on the intention-to-treat (ITT) population, which is defined as all randomized participants. All efficacy analysis results are analyzed in the full analysis set (FAS) and per-protocol set (PPS). The FAS is defined as all randomized patients who received at least one dose of the study drug and had both baseline and at least one post-baseline measurement of primary efficacy. The PPS is defined as all patients who completed the treatment without serious violation of the protocol. The safety analysis is performed in a safety set (SS), which is defined as participants who receive at least one dose of the study drug and at least one assessment of safety data. Categorical data will be expressed as numbers and percentages, and quantitative data will be expressed as means±SD, median, interquartile range (IQR) values, or minimum and maximum. For the primary outcome, the analysis of covariance (ANCOVA) will be performed to compare the 12-month MoCA outcomes (the change in MoCA score from baseline to week 12) between the groups at follow-up adjusting for baseline scores. For secondary and exploratory outcomes, the ANCOVA will also be performed to test for statistical differences between the groups. A repeated-measures analysis of variance (ANOVA) was performed to investigate the time-course of the changes in serum level of Hcy, HS-CRP, and D-dimer from baseline to weeks 4 and 12 within each group and to compare those between two groups. Pearson χ² or Fisher’s exact test will be performed to compare differences in AEs of two groups. Any potential effects related to site differences will be assessed using mixed models. The baseline will be taken as the covariate in the model, and the effect of the center will be considered. In the case of missing data, we will capitalize on multiple imputation techniques to handle the issue of missing data in this study. All statistical analyses will be performed using Statistical Analysis System (SAS Institute, Inc, Gary, NC), and statistical significance was set at p<0.05.

**Register, ethics, and data management**

This study has been prospectively registered on 25 April 2021 at the Chinese Clinical Trial Registry (ChiCTR2100045831). This trial is conducted by the Declaration of Helsinki and Good Clinical Practice Guidelines and approved by the ethics committee institutional review board of each participating center. Any change to the protocol will be approved by the relevant regulatory authorities and require participants to re-consent before continuing in the study. Data were collected on paper first, and then is being entered and managed by a designated Data Manager using EpiData software (EpiData 3.01 for Windows; The EpiData Association, Odense, Denmark). To ensure the accuracy of the data, two data managers will independently carry out data entry and proofreading. The regular oversight will be conducted by an experienced Clinical Research Associate by monitoring the quality, safety, and progress of the study. The database will be locked post reconciliation of all data. The locked database will be provided to the statisticians to conduct the independent statistical analysis. There are no interim analyses planned. Study findings will be disseminated through peer-reviewed publications and presentations at scientific meetings.

**Discussion**

CSVD refers to a syndrome that is characterized by the damage to white and deep grey matter structures of the brain [7]. It is estimated that more than 73% of middle-aged subjects suffer from CSVD, of which 9% are severe CSVD (defined as high white matter hyperintensity burden, lacunar infarction, or microhemorrhage) [29]. Higher white matter hyperintensity burden is related to cognitive dysfunction, and severe CSVD is one of the main risk factors for mild cognitive impairment [29]. Without timely intervention, mild cognitive impairment will eventually lead to moderate to severe dementia [30]. Given that existing prevention and treatment approaches have not yet shown ideal long-term outcomes, developing novel treatment strategies is quite important for patients with CSVD. As a traditional Chinese medicine recipe, Dengyinnaotong Capsule has shown great potential for promoting blood flow, dispelling wind-evil, and improving cognitive function [12–14]. However, the role of Dengyinnaotong Capsule on mild cognitive impairment related to CSVD is unclear. Therefore, a multicenter, randomized, open-label, controlled trial is designed to investigate the efficacy and safety of Dengyinnaotong Capsule on cognitive function in patients with CSVD for the first time.

This trial has several strengths. First of all, this study is designed as a multicenter, randomized, controlled trial. Participants will be recruited from 25 centers in China to ensure the representation of samples. Secondly, this trial focus on participants aged 50–75 years, among which the risks of stroke and dementia are higher [31]. Thirdly, the study outcomes are measured by using both clinician-administered and self-reported methods through a series of psychometric tools, which ensures the availability of good quality data. Fourthly, the data will be managed
under the oversight of an independent Clinical Research Associate, which is critical to the credibility of future findings of this trial. Despite the above strengths, there are still some limitations in the present study. Firstly, due to the different administration dosages of the two groups, the trial is openly labeled. The lack of blinding has the risk of both performance and detection bias. For example, patients or investigators might add concomitant treatments to address insufficient efficacy or manage symptoms or risk based on their beliefs and knowledge about treatment allocation. Secondly, although the vascular cognitive impairment is a gradual process from normal cognitive status to mild cognitive impairment and then dementia, this study only assesses the 12-week treatment outcome and does not seek to assess the long-term efficacy considering the poor compliance among elderly patients. Finally, we only evaluated the efficacy and safety of Dengyinnaoitong Capsule on cognitive function related to CSVD at the specific dose. Dose-exploration study should be carried out in the further to determine the optimal dose of Dengyinnaoitong Capsule for treating mild cognitive impairment related to CSVD.

In summary, the present trial is the first to investigate the efficacy and safety of Dengyinnaoitong Capsule on cognitive function in patients with CSVD. The findings of this study might provide convincing evidence regarding the efficacy of Dengyinnaoitong Capsule on mild cognitive impairment related to CSVD.

**Trial status**

Recruitment started on 10 May 2021 and is foreseen to end on 31 December 2022.

**Abbreviations**

AEs: Adverse effects; MOCA: Montreal Cognitive Assessment; CDR: Clinical dementia rating scale; WMHs: White matter hyperintensities; ADL: Activities of Daily Living; POMA: Performance-oriented mobility assessment; GDS: Geriatric Depression Scale; Hcy: Homocysteine; HS-CRP: High-sensitivity C-reactive protein; SAEs: Serious AEs; ITT: Intention-to-treat; FAS: Full analysis set; PPS: Per-protocol set; SS: Safety set; SD: Standard deviations; IQR: Interquartile range; SAS: Statistical Analysis System.

**Acknowledgements**

None.

**Dissemination policy**

A detailed dissemination policy has been prepared for the project. This includes publication guidelines that set out the authorship criteria for intended publications. Findings will be published in peer-reviewed journals and disseminated through various channels including social media and at national and international meetings.

**Authors’ contributions**

Conception and design, Q.Z., Y.L., and J.L.; literature review, Y.L., J.L., M.T., M.Z., L.Z., J.Z., and Y.L.; drafting article, Y.L., and J.L.; administrative support, F.Y. All the authors have read and approved the final manuscript.

**Funding**

This work was funded by the Shandong Society of Gerontology (number, 202001) and Gerontology, Shandong Administration of Traditional Chinese Medicine (number, 20212050). The funders had no role in the design of the study, in the writing of the protocol, or in the decision to submit for publication. There was no sponsor separate from the funder for the trial.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This trial is conducted by the Declaration of Helsinki and Good Clinical Practice Guidelines and approved by the ethics committee institutional review board of Shandong Second Provincial General Hospital (2021-004-01). Informed consent will be obtained from each participant or each of the participant’s legally responsible relatives. Any change to the protocol will be approved by the relevant regulatory authorities and require participants to re-consent before continuing in the study.

The researchers agreed, when signing the protocol, to adhere to the instructions and procedures described therein and thus to follow the principles of Good Clinical Practice that they imply. The data will be treated anonymously at all times, identifying each patient with a protocol number. The privacy and confidentiality of all data will be protected.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Neurology, Shandong Second Provincial General Hospital, Jinan, Shandong, China. 2. Department of Administration, Shandong Second Provincial General Hospital, Jinan, Shandong, China. 3. Department of Neurology, Jinan Fanggan Rehabilitation Hospital, Jinan, Shandong, China. 4. Department of Neurology, Shandong Second Provincial General Hospital, Shandong University, Jinan, Shandong, China.

Received: 8 December 2021 Accepted: 7 August 2022

Published online: 17 August 2022

**References**

1. Cui Y, Zhang H, Zhao Y, Sun S, Chai Q, Gong G, et al. Home-measured orthostatic hypotension associated with cerebral small vessel disease in a community-based older population. Hypertens Res. 2020;43:798–807.
2. Litak J, Mazurek M, Kulesza B, Szymgin P, Litak J, Kamieniak P, et al. Cerebral Small Vessel Disease. Int J Mol Sci. 2020;21:9729.
3. Reijmer YD, Fotiadis P, Martinez-Ramirez S, Salat DH, Schultz A, Shoamanesh A, et al. Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. Brain. 2015;138:179–88.
4. Mok V, Srinanth V, Xiong Y, Phan TG, Moran C, Chu S, et al. Race-ethnicity and cerebral small vessel disease—comparison between Chinese and White populations. Int J Stroke. 2014;9 Suppl A100:36–42.
5. Consortium M. METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research. Alzheimers Dement. 2016;12:1235–49.
6. Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Okai S, Suzuki J, Sasaki Y, et al. Intravenous infusion of mesenchymal stem cells improves impaired cognitive function in a cerebral small vessel disease model. Neuroscience. 2019;408:361–77.
7. Du J, Zhu H, Zhou J, Lu P, Qiu Y, Yu L, et al. Structural Brain Network Disruption at Preclinical Stage of Cognitive Impairment Due to Cerebral Small Vessel Disease. Neuroscience. 2020;449:99–115.
8. Cannistraro R, Badi M, Edelman BH, Dickson DW, Middlebrooks EH, Meschia JF. CNS small vessel disease: A clinical review. Neurology. 2019;92:1146–56.
9. Li T, Huang Y, Cai W, Chen X, Men X, Lu T, et al. Age-related cerebral small vessel disease and inflamming. Cell Death Dis. 2020;11:932.
10. Shi Y, Wardlaw J. Update on cerebral small vessel disease: a dynamic whole-brain disease. Stroke. 2016;1:83–92.
11. Zhang X, Liu X, Xia R, Li N, Liao X, Chen Z. Chinese herbal medicine for vascular cognitive impairment in cerebral small vessel disease: A protocol for systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2020;99:e22455.
12. Li T, Hui ZS, Shu Y. [The nootropic effect of Dengyinnaotong capsules on aging mice]. Yunnan. J Trad Chin Med. 2009;30:51–52.
13. Chen F-Y, Tian Z-H. Clinical observation of Deng Yin Nao Tong capsule combined with Naotong Capsule in the treatment of convalescent cerebral infarction. Drugs Clinic. 2017;32:38–41.
14. Wu Q-F, Pu J-X, Zhang Y-Y, Zhu H-J, Jia Y, Zhang S-Y, et al. Clinical study of Dengyinnaotong Capsule in the treatment of ischemic stroke in convalescence and sequelae phase (blood stasis blocking collateral syndrome). Chin J Integrative Med Cardio-Cerebrovasc Dis. 2011;10:1068–9.
15. Zhao Q, Guo Q, Li F, Zhou Y, Wang B, Hong Z. The Shape Trail Test: application of a new variant of the Trail making test. PLoS One. 2013;8:e57333.
16. Zhao C, Tsapanou A, Manly J, Schupf N, Brickman AM, Gu Y. Vitamin D intake is associated with dementia risk in the Washington Heights-Inwood Columbia Aging Project (WHICAP). Alzheimers Dement. 2020;16:1393–401.
17. Viscogliosi G, Ettorre E, Chiriac IM. Dementia correlates with anticoagulation underuse in older patients with atrial fibrillation. Arch Gerontol Geriatr. 2017;72:108–12.
18. Branch CMAn, Branch GNGotCMAG. Consensus on Diagnosis and Treatment of Cerebral Small Vascular Disease in China. Chin J Neurol. 2015;48:838–44.
19. Qu J. Clinical study on Yinxiyige Capsules combined with meccobalamin in treatment of cerebrovascular cognitive impairment. Drugs Clinic. 2019;34:2946–50.
20. Shi Y-F, Mou Y-P, Yang J-B. Clinical study of Yinxiyige in the treatment of non-demented vascular cognitive impairment. Guangming J Chin Med. 2017;32:2507–8.
21. Nasreddine ZS, Phillips NA, Bédirian V, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. Bmj. 2013;346:e7586.
22. Peng D. Clinical practice guideline for cognitive impairment of cerebral small vessel disease. Aging Med (Milto). 2019; 2:64–73.
23. Zhao C, Tsapanou A, Manly J, Schupf N, Brickman AM, Gu Y. Vitamin D intake is associated with dementia risk in the Washington Heights-Inwood Columbia Aging Project (WHICAP). Alzheimers Dement. 2020;16:1393–401.
24. Viscogliosi G, Ettorre E, Chiriac IM. Dementia correlates with anticoagulation underuse in older patients with atrial fibrillation. Arch Gerontol Geriatr. 2017;72:108–12.
25. Branch CMAn, Branch GNGotCMAG. Consensus on Diagnosis and Treatment of Cerebral Small Vascular Disease in China. Chin J Neurol. 2015;48:838–44.
26. Qu J. Clinical study on Yinxiyige Capsules combined with meccobalamin in treatment of cerebrovascular cognitive impairment. Drugs Clinic. 2019;34:2946–50.
27. Shi Y-F, Mou Y-P, Yang J-B. Clinical study of Yinxiyige in the treatment of non-demented vascular cognitive impairment. Guangming J Chin Med. 2017;32:2507–8.
28. Nasreddine ZS, Phillips NA, Bédirian V, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. Bmj. 2013;346:e7586.
29. Zhao C, Tsapanou A, Manly J, Schupf N, Brickman AM, Gu Y. Vitamin D intake is associated with dementia risk in the Washington Heights-Inwood Columbia Aging Project (WHICAP). Alzheimers Dement. 2020;16:1393–401.
30. Viscogliosi G, Ettorre E, Chiriac IM. Dementia correlates with anticoagulation underuse in older patients with atrial fibrillation. Arch Gerontol Geriatr. 2017;72:108–12.
31. Corraini P, Henderson VW, Ording AG, Pedersen L, Horváth-Puhó E, Sørensen HT. Long-Term Risk of Dementia Among Survivors of Ischemic or Hemorrhagic Stroke. Stroke. 2017;48:180–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions